Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.7351 per EA under NDC 33342000309. Its NADAC has been published 380 times since May 15, 2019.
FDA first approved this application on Aug 29, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342000309
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA090679FDA Approved
8/29/2018
TE Code
AB
On Market Since
8/30/2018
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 380 times since May 15, 2019, and over the history we have for it it has declined 22.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7351 per EA |
|---|---|
| All-time high | $1.8425 (Oct 16, 2019) |
| All-time low | $0.5570 (Jan 21, 2026) |
| 52-week high | $0.7351 |
| 52-week low | $0.5570 |
| Median price | $0.7530 |
| Average price | $0.8340 |
| Largest weekly change | +57.7% (Aug 21, 2019) |
| Weeks tracked | 380 |
| Tracking since | May 15, 2019 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.7351 per EA (NDC 33342000309), effective Aug 19, 2026.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 22.1%. It has been tracked across 380 weekly CMS publications since May 15, 2019.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since May 15, 2019, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.5570 (Jan 21, 2026) to a high of $1.8425 (Oct 16, 2019), with a median of $0.7530 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMIVUDINE-ZIDOVUDINE TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 33342000309) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.